Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04495478 · ClinicalTrials.gov registry record · Phase 1
A Study of Ramucirumab (LY3009806) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT04495478 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 50 participants.
The verdict
NCT04495478, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study evaluates a new formulation of ramucirumab, a drug approved for several types of cancer. In this study of healthy participants, a small amount of ramucirumab will be given by injection either into a vein or just under the skin. Study doctors will measure the amount of ramucirumab in the bloodstream. Side effects and tolerability will be documented. The study will last for about 16 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.
Interventions
- DRUG Placebo - IV
- DRUG Placebo - SC
- DRUG Ramucirumab - IV
- DRUG Ramucirumab - SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2021-05-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04495478
The ClinicalTrials.gov registry entry for NCT04495478 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo - IV is the first listed.
NCT04495478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04495478 about?
NCT04495478 is a clinical study titled "A Study of Ramucirumab (LY3009806) in Healthy Participants". This study evaluates a new formulation of ramucirumab, a drug approved for several types of cancer. In this study of healthy participants, a small amount of ramucirumab will be given by injection either into a vein or just under the skin. Study doctors will measure the amount of ramucirumab in the ...
What is the current status of trial NCT04495478?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2020-07-30. Estimated completion is 2021-05-09.
What interventions are being tested in trial NCT04495478?
The interventions under investigation include: Placebo - IV (DRUG), Placebo - SC (DRUG), Ramucirumab - IV (DRUG), Ramucirumab - SC (DRUG).
Who is sponsoring clinical trial NCT04495478?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.